Fluorinated Alkylated Bile Acids for Neurodegenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's diseases are ineffective in halting disease progression, and existing treatments for tissue degeneration, including those affecting the neurological system, spinal cord, and ocular tissues, are limited in efficacy, leading to worsening quality of life and increased healthcare burdens.
Innovation Solution
Development of fluorinated and alkylated derivatives of bile acids, specifically compounds like fluorinated UDCA and TUDCA, which inhibit tissue degeneration through mechanisms such as down-regulation of endoplasmic stress response elements and modulation of miRNA gene regulation, offering potential therapeutic benefits for neurodegenerative disorders, diabetes, and metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fluorinated and alkylated derivatives of bile acids are developed, then metabolic stability and binding affinity are improved, but molecular complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of bile acid derivatives through fluorine substitution at different positions (C-3, C-7, C-24) and varying alkyl group configurations. These structural parameter changes enhance metabolic stability and binding affinity while maintaining the core bile acid framework, thereby improving therapeutic reliability without excessive complexity increase.
2Reliability
If fluorinated and alkylated derivatives of bile acids are developed, then binding affinity is improved, but synthesis difficulty increases
Solution Approach 1:
The patent employs segmentation by dividing the synthesis process into modular stages: first establishing the core bile acid structure, then sequentially introducing fluorine atoms at specific positions, and finally adding alkyl groups. This segmented approach allows for controlled synthesis of complex fluorinated derivatives while managing the overall manufacturing complexity through stepwise construction.
3Adaptability or versatility
If existing therapies are used for neurodegenerative disorders, then treatment coverage is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent creates composite therapeutic molecules by combining the hydrophilic bile acid core with hydrophobic fluorinated and alkylated groups. This composite structure enables the derivatives to interact with multiple biological targets simultaneously, including mitochondrial membranes and protein aggregation sites, thereby enhancing therapeutic efficacy across various neurodegenerative disorders while maintaining broad treatment coverage.
Data Source
AI summary
The present invention relates to fluorinated and alkylated bile acids.